Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This dead cat sure is bouncing a lot and I will be happy to buy more cheapies!!!
New to this ticker, but not new to investing.
Saw this for what it was and slapped the Ask when we were 30% down.
Cheers to all those that grabbed some cheapies!
Yes,
And also having the right tool for the right job correct?
Is a chart going to help you right now?
Would inspecting the divergence of volumes seeking patterns and analyzing indicators prepare you for an increase in PPS?
NO it will not; so what mrwrn201 is saying right now makes sense.
This is a penny stock and no matter what the chats say it is only the fundamentals that will have any real influence right now.
Happy trading!
Ya that sounds as scary as Purdue having to much overhead for the billions a year they rake in.
OMG the sky is falling!
We are speaking about veterans who understand lack of "eloquence" correct?
"Charts prove nothing"
WHAT!?
Charts record PPS, (you know the same PPS you report every time we are red).
REALLY!?
Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
BY Business Wire
— 8:00 AM ET 08/11/2014
NEW YORK--(BUSINESS WIRE)-- Rodman & Renshaw Conferences, LLC, today announced that – former United States Secretary of State and retired four star general – Colin L. Powell will present the keynote address for the 2014 Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, at The Palace Hotel in New York. General Colin L. Powell’s address is scheduled for Tuesday, September 9, 2014 at 8:00am in the Villard Ballroom. The Conference will be held September 9 and 10, 2014 with more than 250 public & private companies from around the world expected to present to an audience of over 2,000 attendees. The two day event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities. Institutional investors, venture capitalists, private equity firms, sophisticated private investors and industry executives are welcome to attend this conference. Register online at the Rodman & Renshaw Conference website at www.rodm.com or contact Lily Khaykina, Rodman & Renshaw’s Conference Manager, at (212) 356-0529 or via e-mail at LK@rodm.com
Thanks for that PPS update! Where was that update when we were up 8%???
Hmmmm....
Dude! THIS! If there was ever a better meme!!!!
LPC good deal #2 ACTIVATE~!
LOL! LOL!
Plunge?
I will assume this an example of salmon swimming upstream and taken the “plunge” up the waterfall from .125
20 Million = .125
I am sure we are higher than .125 and soon to go much higher.
Pharma's would be smart to offer 5 Billion now before ART hits the market lol!
So the question is, (and this is a “What If” question) that *Narcan* that is used as a very aggressive substance to pull someone that Overdosed back to the living *Time Released* into your liver?
Is this the question?
Is Narcan ok to be slowly released over time into a person’s liver? What are the long term effects of this?
I do not know, but I don’t think it would be good.
Appreciate the VTX reading, but indicators such as VTX is really only good for showing consolidation.
Please read here: http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:vortex_indicator
Notice how our current pattern is breaking apart and will be come back together. This pattern is simply showing the same thing as the BB bands. Most likely we will break at 1.7 to 1.10 and head back down. Even knowing this proves nothing and means nothing because we are talking about a penny stock where shares can be traded easily.
I could just as easily present 3 other indicators to paint a picture of steady growth ahead. Charts are pointless at this point; its really all about the news.
You heard it here first folks! Nasrat has been accused of hyping ELTP's stock.
Yup the very same upstanding gentleman described from this Bio below:
Mr. Nasrat Hakim has been the Chief Executive Officer and President of Elite Pharmaceuticals, Inc. since August 1, 2013. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He has a proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. He served as a Vice President of Quality Compliance and Technical Services at Actavis LLC. Mr. Hakim served as Vice President of Quality of Alexza Pharmaceuticals Inc. since July 18, 2007. Mr. Hakim served as Corporate Vice President of Quality and Compliance for Actavis / Alpharma Inc., and previously served as Global Vice President of Compliance for Alpharma, where he was employed from 2004 to 2007. He has been a Director at Elite Pharmaceuticals, Inc since August 1, 2013. Mr. Hakim has also served as Executive Director of Corporate Compliance and Technical Projects for Watson Pharmaceuticals and Executive Director, Site Head of Quality and Compliance at TheraTech, Inc. Watson Pharmaceuticals acquired TheraTech in 1999. Mr. Hakim holds both a JD and BS in Law from Saratoga University in San Jose, California, a Masters degree (LLM) in Law from St. Thomas University in Miami, Florida and Bachelors and Masters degrees in Chemistry from California State University at Sacramento.
Yup, totally sounds like this sort would resort to such trickery.
I bet if we dig a little deeper we will find all kinds of shenanigans!
Let's see what he has been up to:
• Twenty six years of pharmaceutical and medical industry experience in Quality Assurance, Quality Control, AR&D and Regulatory Compliance.
• Educational discipline in Law (JD/LLM), Business, Regulatory Affairs (RAC) and Chemistry/Bio-Chemistry (MS).
• Proven management experience establishing new departments, building cross-functional teams, creating sustainable GxP-compliant programs and preparing domestic and international sites for successful FDA/regulatory inspections.
• Extensive quality experience designing and implementing Corporate Quality Systems impacting multiple sites, and managing internal and external compliance oversight and risk assessment.
• In-depth technical knowledge of quality and manufacturing systems and technologies including immediate and extended release formulations used in solid dosage, transdermals, (Medical Device) insert and implant finished products.
• Solid regulatory command of GMP’s, national and International regulations. Ability to research, analyze and implement systems to comply with global regulations in support of timely and successful new product applications.
• Successful change agent via creation and implementation of global compliance program and remediation of existing programs and systems across multiple sites.
Ok, but with a terrible track record such as this guys he must have hardly any connection right!?
LOL! 500+ connections
http://www.linkedin.com/pub/nasrat-hakim/6/261/293
Just read the recent 10Q
http://archive.fast-edgar.com//20140520/APA2U22C6222N2U2222E2CZ2DFMC32227262/
Basically this company is a cash burn and relying on nothing but future hype to sell shares.
"Net Loss
Net loss for the period from April 11, 2011, (inception of development stage) through March 31, 2014, was $(1,693,730).
Liquidity and Capital Resources
As at March 31, 2014, the Company had a cash balance and asset total of $378 and $112,134 respectively, compared with $4,683 and $103,996of cash and total assets, respectively, as at June 30, 2013. The decrease in cash was due to normal operating activities whereas the increase in total assets was due to the purchase of inventory for operations.
As at March 31, 2014, the Company had total liabilities of $652,002compared with $651,100as at June 30, 2013. The increasein total liabilities was attributed to the increase in accounts payable and accrued liabilities.
The overall working capital increasedfrom $645,772deficit at June 30, 2013, to $644,938deficit at March 31, 2014.
Cashflow from Operating Activities
During the nine monthsended March 31, 2014, cash used in operating activities was$(235,333) compared to $(371,120)for the nine months ended March 31, 2013. The increase in the amounts of cash used for operating activities was primarily due to interest expense, an increase in accounts payable and the net loss.
Cashflow from Investing Activities
During the nine months ended March 31, 2014, cash used in investing activities was $(10,018) compared to $119,749 for the nine months ended March 31, 2013. This change is due to the Company deciding to no longer support mineral claims and therefore took an asset impairment charge equal to the amount of the mineral claims of $124,911.
Cashflow from Financing Activities
During the nine months ended March 31, 2014, cash provided by financing activity was $241,046 compared to $246,481for the nine months ended March 31, 2013.The decrease in cash provided by financing activities is due to decrease in Related Party loans.
Quarterly Developments
On March 12, 2014, the Company filed a Certificate of Amendment with the Nevada Secretary of State to increase its authorized capital to Two Billion Five HundredFiftyMillion shares (2,550,000,000) of which Two Billion Five Hundred Million (2,500,000,000) shall be shares of Common Stock, par value $0.00001 per share, and Fifty Million (50,000,000) shall be shares of Preferred Stock, par value $0.00001,(the “Increase in Authorized”). The Increase in Authorized was effective with the Nevada Secretary of State on March 12, 2014, when the Certificate of Amendment was filed. The Increase in Authorized was approved by the Board of Directors and the shareholders holding a majority of the total issued and outstanding shares of common stock on March 4, 2014.
Subsequent Developments
On May 5, 2014, the effective date, the Company entered into an Asset/Intellectual Property Purchase Agreement with Classic Capital Inc. Intellectual assets purchased relate to Bitcoin mining, pool development, operations, and server development.
On May 5, 2014, the Company entered into a Convertible Promissory Note with Classic Capital Inc. in accordance with the terms of the asset acquisition agreement in the sum of $150,000 with a May 5, 2015 maturity date.
On May 15, 2014, the Company entered into an Employment Agreement (the “Agreement”) with Brett Everett (“Mr. Everett”) an individual. Pursuant to the terms and conditions of the Agreement, Mr. Everett shall serve
27
as the Corporation’s President and Chief Executive Officer and shall assume such other positions as reasonable requested by the Board of Directors, commencing on May 15, 2014 for a term of one (1) year, During the term of this agreement termination can be done by giving one month’s written notice of termination or at the discretion of the Company, payment in lieu of notice (based on the Contract Rate, as defined below, for one month), or some combination thereof.. In exchange for his services, Mr. Everett shall receive a monthly salary of Three Thousand Dollars ($3,000) which may be converted into shares of the Company’s common stock, at the sole discretion of the Company, per the terms and conditions of the Agreement. Mr. Everett will also receive a Five Thousand Five Hundred Dollar ($5,500) signing bonus for agreeing to the contract with the Company.
The foregoing summary description of the terms of the Agreement may not contain all information that is of interest to the reader. For furtherinformation regarding the terms and conditions of the Agreement, this reference is made to such agreement, which is filed as Exhibit 10.24, hereto and is incorporated herein by this reference.
Going Concern
We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive acquisitions and activities. For these reasons, our auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing.
Future Financings
We will continue to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund our operations and other activities."
My thoughts:
No delusions going on here people, this is a flipper.
Not saying you can't make money, but don't get caught holding the bags. Peace out!
MM's just sent a trade code: 100
"100 I need shares."
Sure, if they can get past phase one LOL!
http://www.signaturerx.com/view.cfm/6/Pipeline
About Evaluate:
Founded in 1996 by Dr. Jonathan de Pass
Headquartered in London with staff in Europe, United States, Japan and India
Currently over 85 analysts and about 150 employees globally
US office was established in Boston, MA in 2011 and is headed by Ms. Debbie Paul
Formally introduced to Japan in 2011 with the help of UKTI (UK Trade and Investment)
Our Editorial Team is EP Vantage and was founded in 2007
Evaluate won the Queens Award for Enterprise International Trade in 2009
EP Vantage won the Commentator of the Year prize at the 2011 European Mediscience Awards
Key services include: EvaluatePharma, EvaluateMedTech and EvaluateClinical Trials
We proudly serve over 200 clients globally and have thousands of users
VISION AND HISTORY
Evaluate Group was established in 1996 by Dr. Jonathan de Pass, a former medical practitioner and a top-ranked pharmaceutical industry analyst. Dr. de Pass realized that the health care market needed a better way to get forward-looking market intelligence and the latest news and analysis in order to make sound business decisions for investment and growth.
Over the years, EvaluatePharma has become the industry leader in consensus forecast analysis of the biotech and pharma sector. In 2011 EvaluateClinical Trials was launched to provide deeper insight into global R&D intelligence and analysis, and in 2012 EvaluateMedTech set a new standard in integrated analysis and consensus forecasts to 2020 of the medical device and diagnostic industry.
Dr. de Pass’ vision has been, and continues to be, to make Evaluate the market intelligence and analysis service of choice in the life sciences industry, providing massive productivity gains and must-have data and analysis to its users. This is achieved through our client focus and engagement, and our continual investment in our services to support our clients' business objectives. At its utmost, Evaluate’s vision is to help speed innovation, value and sustainability to the healthcare industry and the patients it serves, by providing trusted intelligence our clients can act on.
OUR CLIENTS
We are a highly trusted partner to our clients...
Large-cap Pharma, Biotech and MedTech companies
Mid-cap Pharma, Biotech and MedTech companies
Small Pharma and Biotech and MedTech companies
Investment Banks, Private Equity firms, Fund Managers, VCs
Management Consultancies and Industry Specialty Consultancies
Healthcare Companies: Insurers, Pharmacies, etc.
Marketing companies working in Life Science
Media Companies
Others Service Providers to industry CMOs, CROs, Industry Consultants, Logistics, Manufacturing, etc.
...and are proud of our ~95% client retention rate.
Staying on topic on “On Topic” I would like to add a caveat.
I will assume that questioning the legitimacy of Nasrat’s comments, or even ELTP as a company is allowed. But I would think that questioning the FDA, or in fact the SEC, (This is who ELTP files with) is not as easy to get away with.
We can ponder all day about ELTP, but to make any posts that questions the FDA, or the SEC, (BTW Nasrat is working closely with the FDA and also files with the SEC) should be closely scrutinized.
Wouldn’t you agree?
I am sure some will disagree with my statement, but there should no longer be any concerns of ELTP's future.
"Elite's balance sheet was also its strongest on record, reporting a working capital surplus of $3.8 million, the first working capital surplus in 5 years."
Please make note that in this article is specifically says:
"ImpressivePennyStocks is owned and operated by FlipVentures LLC. FlipVentures LLC has not been compensated for any marketing or promotional effort on ELTP."
Misfit Investments team has done the DD and we feel very good about the information being reported by AMMX.
Some good questions:
Is the deal real?
Will they have to file at some point?
Are they already filing in some fashion that is not reported to the public?
Good questions! :)
I asked all these questions months ago as well, but with great DD from my colleagues I am certain of AMMX's success..
*note*
Do not let these bear raids fool you, people are very interested in this company and are going to try and move you out so that they can get in. It is amazing how a little tree shaking can loosen so many ripe shares...
Trust Me .... pleaseeee! I am a long, short, trader, flipper; I am confused. The only thing that I know for sure is that I have one account with 10 shares in it. Whew! Guess that makes me a long?
PPS updates and LVL 2 updates! Oh My!
"Elite will be $1.00 by the end of the week and $2.00 by the end of the month"
I am not sure who would post such a satire remark, but surely I would assume that we would all see such a post as pure Jest!
Please provide the name of the person that provided me such laughter this morning so I can thank them!
The winnings are factual without argument. A win is a win. Do you Deny that Elite has had wins, well from forever?
"preferred shares"
Why don't you explain to everyone what these "preferred shares" are meant for? Who has control of them? And why there was a land slide vote in favor for them?
Just the facts please, thank you!
Awesome!
TY for the update and keep the info coming! :)
But we were promised .125!!! Baaaaahaaaaaaaahhhhhwaaaaaaa!!!!
I honestly share none of his concerns. I would first have to admit that his concerns have merit and they don't.
Asking for simplicity is clearly asking for to much...
Yes, if we listened to such advise we would have all sold at .125
I am happy to say that I do not listen to crazy advise like that.
"I should definitely follow "
The irony here is killing me...
Yes,
Misfit Investments is in AMMX
You been watching this one for awhile too!? Wowsers! What a coincidence!
"manufacturing expertise"
This can't be stated enough! Also his long standing connections to Nasrat, EPIC, and many other ect... makes him a networking asset.
So enlightening, tell us more...
I am sure you have a great reason for this comment.
Absolutely! I agree!